Valuation: Nutriband Inc.

Market Cap 35.62M 31.34M 29.12M 26.74M 50.19M 3.44B 51.03M 346M 135M 1.69B 134M 131M 5.83B P/E 2025
-8.39x
P/E 2026 -1.86x
Enterprise Value 31.29M 27.53M 25.58M 23.49M 44.09M 3.02B 44.83M 304M 119M 1.48B 117M 115M 5.12B EV / Sales 2025
41.1x
EV / Sales 2026 26.5x
Free-Float
43.12%
Yield 2025 *
-
Yield 2026 -
1 day+1.71%
1 week-4.79%
Current month-6.58%
1 month-2.30%
3 months-25.69%
6 months-37.92%
Current year-34.36%
1 week 2.92
Extreme 2.92
3.16
1 month 2.91
Extreme 2.91
3.44
Current year 2.9
Extreme 2.9
4.98
1 year 2.9
Extreme 2.9
8.99
3 years 1.53
Extreme 1.53
11.78
5 years 1.53
Extreme 1.53
12.86
10 years 0.86
Extreme 0.8571
43.54
Manager TitleAgeSince
Chief Executive Officer 35 01/01/2016
Chief Executive Officer 52 -
Director of Finance/CFO 77 02/09/2020
Director TitleAgeSince
Chairman 52 21/01/2022
Director/Board Member 48 01/07/2018
Director/Board Member 38 01/07/2018
Date Insider Type Main position Quantity % Market Cap.
31/01/25 Option

Chief Financial Officer

212,837 1.9164%
31/01/25 Other

Founder

126,833 1.1420%
20/03/24 Free

Founder

97,500 1.2447%
Change 5-day change 1-year change 3-year change Capi.($)
+1.71%-4.79%-65.51%-21.37% 35.62M
+2.29%+4.28%-18.10%-9.83% 175B
+1.46%-0.42%-9.56%-6.46% 105B
+1.58%+0.62%+5.61%+60.91% 59.35B
-1.13%-1.96%+32.11%+56.38% 50.71B
+2.22%-2.23%-14.36%-40.96% 42.15B
+2.98%-5.74% - - 31.82B
+1.50%-8.26%-17.23%-45.22% 27.2B
-7.67%-9.45%+44.38%-13.02% 25.11B
+1.63%-3.19%-5.06%-7.76% 20.53B
Average +0.66%-3.72%-5.30%-3.04% 53.74B
Weighted average by Cap. +1.23%-1.51%-4.52%+1.24%

Financials

2025 2026
Net sales 2.14M 1.88M 1.75M 1.61M 3.02M 207M 3.07M 20.78M 8.11M 101M 8.03M 7.86M 350M 2.04M 1.79M 1.67M 1.53M 2.87M 197M 2.92M 19.78M 7.72M 96.39M 7.65M 7.48M 334M
Net income -10.48M -9.22M -8.57M -7.87M -14.77M -1.01B -15.02M -102M -39.75M -496M -39.35M -38.5M -1.72B -8.23M -7.24M -6.73M -6.18M -11.6M -795M -11.79M -79.92M -31.21M -390M -30.89M -30.23M -1.35B
Net Debt -4.13M -3.63M -3.37M -3.1M -5.81M -398M -5.91M -40.06M -15.64M -195M -15.49M -15.15M -676M -4.33M -3.81M -3.54M -3.25M -6.1M -418M -6.2M -42.05M -16.42M -205M -16.25M -15.9M -709M
Logo Nutriband Inc.
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Employees
-
Date Price Change Volume
24/07/26 $2.980 +1.71% 21,825
23/07/26 $2.930 -3.93% 13,734
22/07/26 $3.050 -0.97% 7,027
21/07/26 $3.080 0.00% 4,874
20/07/26 $3.080 -0.96% 3,951
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.930USD
Average target price
15.00USD
Spread / Average Target
+411.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NTRB Stock